TOH edition: Thursday, 15 October 2026 · Health & Medicine
More time before cancer returns: adding an mRNA vaccine to treatment slowed melanoma’s return and spread in a late-stage trial
Reported by bostonglobe.com
Publisher date:
Merck and Moderna reported that adding their personalised mRNA cancer vaccine to Keytruda slowed melanoma’s return and spread in a late-stage trial. The finding strengthens the case for training the immune system to attack cancer, but detailed data remain pending and success against other cancers is not established.
The reported melanoma result offers evidence that cancer vaccines could help keep disease at bay longer, even as their usefulness against other cancers remains uncertain.
Read the original report at bostonglobe.com (opens in a new tab) →
Read the full front page of Thursday, 15 October 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.